Mounjaro weight loss results: what to expect and how to read the evidence

What the SURMOUNT-1 numbers actually measured

The most important context for any weight loss result from a clinical trial is who was in it. SURMOUNT-1 enrolled adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, who did not have type 2 diabetes. Every participant also followed a reduced-calorie diet and increased their physical activity. That support structure matters: the medicine worked alongside lifestyle changes, not instead of them.

At 72 weeks, the average reductions were roughly 15% at 5mg, 19% at 10mg, and 20–21% at 15mg. The placebo group, who received the same diet and activity support, lost around 3%. So the medicine's contribution above lifestyle alone was substantial. Around a third of participants on the highest dose lost 25% or more of their starting weight. That tail of strong responders skews the averages slightly upward, which is worth knowing if your own progress feels slower than the headlines suggest.

The NICE appraisal of tirzepatide (TA1026) reviewed this evidence and recommended the medicine for NHS use, describing the weight loss as clinically meaningful and sustained across the trial period. The committee also noted that indirect comparisons favoured tirzepatide over semaglutide 2.4mg, a finding later confirmed directly in the SURMOUNT-5 head-to-head trial published in 2025, where tirzepatide produced greater average loss than semaglutide at the doses compared.

One detail worth holding onto: 72 weeks is about 18 months. The results you see cited are not from a three-month trial.

Why the timeline matters more than the first-week number

A question our prescribers hear regularly is some version of: "I've been on it two weeks and I've only lost a couple of pounds, is it working?" Almost always, the answer is yes.

Treatment starts at 2.5mg, a dose whose job is to help your body adjust, not to produce the full effect. Most of the dose titration happens across the first several months. If you want a detailed breakdown of what changes week by week, the week-one experience and four-week results pages cover the early phase specifically. The fuller clinical picture, including when most people reach their peak loss, is covered on the timeline page.

The practical shape of it: appetite suppression tends to arrive early, often within the first injection or two. Scale movement follows, gradually at first, then more noticeably once you're past the starter doses. People who track consistently often find they've lost more than they felt they had. Weight loss on tirzepatide is not a straight line, and weeks where nothing moves are normal. Progress is measured in months, not days.

On timing: if you're ordering around a bank holiday or planning to start treatment before a holiday, factor in that pricing and availability can shift, and same-day dispatch depends on ordering before 12pm on a working day. Worth planning ahead rather than scrambling.

What affects how much weight you lose, and why results vary

The trial average is a useful anchor but not a prediction. Several factors pull individual results above or below it. Starting BMI matters: people with higher starting weights tend to lose more in absolute kilograms but sometimes similar percentages. Whether you have type 2 diabetes also affects response, SURMOUNT-2 tested tirzepatide in adults with both obesity and diabetes and found meaningful reductions, though somewhat smaller on average than SURMOUNT-1.

Dose reached is significant. Not everyone titrates to 15mg; some people stay at a lower dose because it works well enough, or because side effects are better managed there. The data shows a dose-response relationship (higher doses tend to produce greater loss) but a prescriber's job is to find the right dose for you, not the highest one. If you feel your progress has stalled or the medicine has stopped working as it did initially, that's a conversation for your clinical team rather than a reason to self-adjust. The common questions about plateaus page addresses this in detail.

Lifestyle factors matter too. The trial results came from people who also changed their eating and activity, the medicine works best as part of that broader picture, which is why weight management at nume is framed around the whole approach, not just the prescription. For a fuller picture of how the medicine works mechanically, the Mounjaro overview covers the dual GIP and GLP-1 mechanism clearly.

What the evidence does not tell you, and where clinical assessment fills the gap

Clinical trials tell us what happened on average in a carefully selected group. They cannot tell you your individual trajectory, whether Mounjaro or Wegovy is the better fit for you, or whether a particular dose will suit your tolerance. That's not a flaw in the evidence, it's just what trials are for.

For people who want to look at this across treatment approaches, the tirzepatide results comparison page sets Mounjaro's numbers alongside semaglutide's trial data in a structured way, with the differences explained plainly. The results summary page pulls the key figures together without the deeper trial breakdown, if you want a shorter reference.

Mounjaro is a prescription-only medicine, which means suitability is always assessed by a prescriber, the evidence gives you an informed starting point, not a guaranteed outcome. At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber. If you're weighing the evidence and wondering whether treatment is right for you, starting a free consultation is the next step.